{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:22:30Z","timestamp":1791930150601,"version":"4.3.4"},"reference-count":158,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pediatric acute lymphoblastic leukemia (ALL) is the most common subtype of childhood leukemia, which is characterized by the abnormal proliferation and accumulation of immature lymphoid cell in the bone marrow. Although the long-term survival rate for pediatric ALL has made significant progress over years with the development of contemporary therapeutic regimens, patients are still suffered from relapse, leading to an unsatisfactory outcome. Since the immune system played an important role in the progression and relapse of ALL, immunotherapy including bispecific T-cell engagers and chimeric antigen receptor T cells has been demonstrated to be capable of enhancing the immune response in pediatric patients with refractory or relapsed B-cell ALL, and improving the cure rate of the disease and patients\u2019 quality of life, thus receiving the authorization for market. Nevertheless, the resistance and toxicities associated with the current immunotherapy remains a huge challenge. Novel therapeutic options to overcome the above disadvantages should be further explored. In this review, we will thoroughly discuss the emerging immunotherapeutics for the treatment of pediatric ALL, as well as side-effects and new development.<\/jats:p>","DOI":"10.3389\/fimmu.2022.921894","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T04:25:22Z","timestamp":1655094322000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives"],"prefix":"10.3389","volume":"13","author":[{"given":"Meng","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabing","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.04.038","article-title":"Genomic Profiling of Adult and Pediatric B-Cell Acute Lymphoblastic Leukemia","volume":"8","author":"Liu","year":"2016","journal-title":"EBioMedicine"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)33018-1","article-title":"Acute Lymphoblastic Leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000810","article-title":"The Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immunotherapy for the Treatment of Acute Leukemia","volume":"8","author":"Boyiadzis","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.6004\/jnccn.2020.0001","article-title":"Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Brown","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.1636","article-title":"Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.37.8018","article-title":"Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1400972","article-title":"Acute Lymphoblastic Leukemia in Children","volume":"373","author":"Hunger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004043","article-title":"How I Treat Relapsed Acute Lymphoblastic Leukemia in the Pediatric Population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-3962","article-title":"The Tumor Microenvironment Innately Modulates Cancer Progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The Tumor Microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","article-title":"The Updated Landscape of Tumor Microenvironment and Drug Repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer Immunotherapy: The Beginning of the End of Cancer","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-017-0453-8","article-title":"Immunotherapy in Hematologic Malignancies: Past, Present, and Future","volume":"10","author":"Im","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218000","article-title":"Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches","volume":"21","author":"Noh","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03106","article-title":"Immunotherapy for Hematologic Malignancies","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","article-title":"Immune Checkpoint Blockade and CAR-T Cell Therapy in Hematologic Malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16","volume":"37","author":"Jeha","year":"2019","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30031-2","article-title":"Comparative Features and Outcomes Between Paediatric T-Cell and B-Cell Acute Lymphoblastic Leukaemia","volume":"20","author":"Teachey","year":"2019","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10555-019-09834-0","article-title":"Immunotherapy in Pediatric Acute Lymphoblastic Leukemia","volume":"38","author":"Inaba","year":"2019","journal-title":"Cancer Metastasis Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature25795","article-title":"Pan-Cancer Genome and Transcriptome Analyses of 1,699 Paediatric Leukaemias and Solid Tumours","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-0779","article-title":"Opportunities and Challenges in Drug Development for Pediatric Cancers","volume":"11","author":"Laetsch","year":"2021","journal-title":"Cancer Discov"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41408-018-0117-0","article-title":"Survival After Blinatumomab Treatment in Pediatric Patients With Relapsed\/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"8","author":"Gore","year":"2018","journal-title":"Blood Cancer J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41408-020-00342-x","article-title":"Blinatumomab in Pediatric Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia: Results of the RIALTO Trial, an Expanded Access Study","volume":"10","author":"Locatelli","year":"2020","journal-title":"Blood Cancer J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005579","article-title":"Blinatumomab In Pediatric Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia: RIALTO Expanded Access Study Final Analysis","volume":"6","author":"Locatelli","year":"2022","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-Risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-Lineage Acute Lymphoblastic Leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/mph.0000000000002419","article-title":"Assessment of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: A Multicenter Study From Turkey","volume":"44","author":"T\u00fcfek\u00e7i","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0140-6736(21)01222-8","article-title":"KTE-X19 for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukaemia: Phase 2 Results of the Single-Arm, Open-Label, Multicentre ZUMA-3 Study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 Anti-CD19 CAR T-Cell Therapy in Adult Relapsed\/Refractory Acute Lymphoblastic Leukemia: ZUMA-3 Phase 1 Results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41571-021-00537-6","article-title":"KTE-X19 Efficacious in Adults With B-ALL","volume":"18","author":"Killock","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02262","article-title":"Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61403-3","article-title":"T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-Escalation Trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.03279","article-title":"CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-Independent Activation Enhances the Efficacy of 4-1BB-Costimulated CD22 CAR T Cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-Cell Therapy in Refractory or Relapsed B Acute Lymphoblastic Leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T Cells With Dual Targeting of CD19 and CD22 in Pediatric and Young Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T Therapy Induces Sustained Remission in Children With R\/R B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T Cell Expansion and Prolonged Persistence in Pediatric Patients With ALL Treated With a Low-Affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8(+) T Cells in Cancer and Cancer Immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer Immunoediting and Resistance to T Cell-Based Immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific Antibodies: A Mechanistic Review of the Pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","article-title":"Bispecific Antibodies in Cancer Immunotherapy","volume":"65","author":"Rader","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.2146\/ajhp150134","article-title":"Blinatumomab: A Novel, Bispecific, T-Cell Engaging Antibody","volume":"73","author":"May","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.2098","article-title":"A Recombinant Bispecific Single-Chain Antibody, CD19\u2009\u00d7\u2009CD3, Induces Rapid and High Lymphoma-Directed Cytotoxicity by Unstimulated T Lymphocytes","volume":"95","author":"Lo\u00fcffler","year":"2000","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00194","article-title":"Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers","volume":"2","author":"Orentas","year":"2012","journal-title":"Front Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: A Biomarker for B Cell Development, Lymphoma Diagnosis and Therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020426","article-title":"Blinatumomab in Children and Adolescents With Relapsed\/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana Di Ematologia E Oncologia Pediatrica) Centers","volume":"14","author":"Beneduce","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122544","article-title":"Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review)","volume":"10","author":"Queudeville","year":"2021","journal-title":"J Clin Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a Bispecific T-Cell Engager (BiTE((R))) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41408-017-0023-x","article-title":"CD19-Negative Relapse of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia Following Blinatumomab Treatment","volume":"7","author":"Mejstrikova","year":"2017","journal-title":"Blood Cancer J"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.241596","article-title":"Immunophenotypic Changes of Leukemic Blasts in Children With Relapsed\/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Who Have Been Treated With Blinatumomab","volume":"106","author":"Mikhailova","year":"2021","journal-title":"Haematologica"},{"key":"B59","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-015-0213-6","article-title":"Increase of PD-L1 Expressing B-Precursor ALL Cells in a Patient Resistant to the CD19\/CD3-Bispecific T Cell Engager Antibody Blinatumomab","volume":"8","author":"K\u00f6hnke","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12357","article-title":"T-Cell Responses Against CD19+ Pediatric Acute Lymphoblastic Leukemia Mediated by Bispecific T-Cell Engager (BiTE) are Regulated Contrarily by PD-L1 and CD80\/CD86 on Leukemic Blasts","volume":"7","author":"Feucht","year":"2016","journal-title":"Oncotarget"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3960","article-title":"Prognostic Significance of Fluorescence Intensity of Surface Marker Expression in Childhood B-Precursor Acute Lymphoblastic Leukemia. A Pediatr Oncol Group Study","volume":"89","author":"Borowitz","year":"1997","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-164129","article-title":"CD20 Up-Regulation in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia During Induction Treatment: Setting the Stage for Anti-CD20 Directed Immunotherapy","volume":"112","author":"Dworzak","year":"2008","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01564","article-title":"Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies","volume":"39","author":"Lussana","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-021-0835-8","article-title":"Preclinical Characterization and Comparison Between CD3\/CD19 Bispecific and Novel CD3\/CD19\/CD20 Trispecific Antibodies Against B-Cell Acute Lymphoblastic Leukemia: Targeted Immunotherapy for Acute Lymphoblastic Leukemia","volume":"16","author":"Wang","year":"2021","journal-title":"Front Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140154","article-title":"Preclinical Study of a Novel Tri-Specific Anti-CD3\/CD19\/CD20 T Cell-Engaging Antibody As a Potentially Better Treatment for NHL","volume":"136","author":"Zhang","year":"2020","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T Design: Elements and Their Synergistic Function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2021.32","article-title":"Chimeric Antigen Receptor Engineered T Cells and Their Application in the Immunotherapy of Solid Tumours","volume":"24","author":"Mao","year":"2022","journal-title":"Expert Rev Mol Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T Cell Therapy: Current Limitations and Potential Strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1711886","article-title":"Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy","volume":"377","author":"Rosenbaum","year":"2017","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-To-Treat Leukemia Remission by CD19 CAR T Cells of Defined Formulation and Dose in Children and Young Adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and Response After CD19-Specific CAR T-Cell Therapy in Pediatric\/Young Adult Relapsed\/Refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1172\/jci125423","article-title":"CD19 CAR T Cell Product and Disease Attributes Predict Leukemia Remission Durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1172\/jci85309","article-title":"CD19 CAR-T Cells of Defined CD4+:CD8+ Composition in Adult B Cell ALL Patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25108","article-title":"Potent Anti-Leukemia Activities of Humanized CD19-Targeted Chimeric Antigen Receptor T (CAR-T) Cells in Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J Hematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000169","article-title":"CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow Cytometric Study of Potential Target Antigens (CD19, CD20, CD22, CD33) for Antibody-Based Immunotherapy in Acute Lymphoblastic Leukemia: Analysis of 552 Cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-Chimeric Antigen Receptors Targeting B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 Expression in Acute Lymphoblastic Leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441","article-title":"CD22-Targeted CAR T Cells Induce Remission in B-ALL That is Naive or Resistant to CD19-Targeted CAR Immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T Cells Targeting Both CD19 and CD22 for Therapy of Adults With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-Engineered Universal CD19\/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated With CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25315","article-title":"Neurotoxicity After CTL019 in a Pediatric and Young Adult Cohort","volume":"84","author":"Gofshteyn","year":"2018","journal-title":"Ann Neurol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1097\/ccm.0000000000002053","article-title":"Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0421-7","article-title":"A Safe and Potent Anti-CD19 CAR T Cell Therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the Beast: CRS and ICANS After CAR T-Cell Therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112845","article-title":"From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives","volume":"10","author":"Voynova","year":"2021","journal-title":"Cells"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.728962","article-title":"CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report","volume":"12","author":"Sun","year":"2021","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A Novel Chimeric Antigen Receptor Containing a JAK-STAT Signaling Domain Mediates Superior Antitumor Effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0793-1","article-title":"Leukemia-Induced Dysfunctional TIM-3(+)CD4(+) Bone Marrow T Cells Increase Risk of Relapse in Pediatric B-Precursor ALL Patients","volume":"34","author":"Blaeschke","year":"2020","journal-title":"Leukemia"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003176","article-title":"Switch Receptor T3\/28 Improves Long-Term Persistence and Antitumor Efficacy of CAR-T Cells","volume":"9","author":"Zhao","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.845499","article-title":"Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function","volume":"13","author":"Blaeschke","year":"2022","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12885-022-09489-1","article-title":"Humanized CD19 CAR-T Cells in Relapsed\/Refractory B-ALL Patients Who Relapsed After or Failed Murine CD19 CAR-T Therapy","volume":"22","author":"An","year":"2022","journal-title":"BMC Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of Cancer Immunity and the Cancer-Immune Set Point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13746","article-title":"Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia","volume":"39","author":"Kang","year":"2019","journal-title":"Anticancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30167-x","article-title":"Nivolumab for Classical Hodgkin's Lymphoma After Failure of Both Autologous Stem-Cell Transplantation and Brentuximab Vedotin: A Multicentre, Multicohort, Single-Arm Phase 2 Trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01389","article-title":"Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002403","article-title":"Phase 2 Study of Pembrolizumab for Measurable Residual Disease in Adults With Acute Lymphoblastic Leukemia","volume":"4","author":"Cassaday","year":"2020","journal-title":"Blood Adv"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006831","article-title":"Outcome of Donor-Derived TAA T Cell Therapy in Patients With High-Risk or Relapsed Acute Leukemia Post Allogeneic BMT","volume":"6","author":"Kinoshita","year":"2022","journal-title":"Blood Adv"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01158.x","article-title":"Quantitative Assessment of WT1 Gene Expression After Allogeneic Stem Cell Transplantation is a Useful Tool for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia","volume":"82","author":"Candoni","year":"2009","journal-title":"Eur J Haematol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-144071","article-title":"Ex Vivo Characterization of Polyclonal Memory CD8+ T-Cell Responses to PRAME-Specific Peptides in Patients With Acute Lymphoblastic Leukemia and Acute and Chronic Myeloid Leukemia","volume":"113","author":"Rezvani","year":"2009","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-351239","article-title":"Targeting Survivin Overcomes Drug Resistance in Acute Lymphoblastic Leukemia","volume":"118","author":"Park","year":"2011","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.trecan.2020.09.002","article-title":"The Anticancer Potential of T Cell Receptor-Engineered T Cells","volume":"7","author":"Ecsedi","year":"2021","journal-title":"Trends Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40364-021-00316-6","article-title":"Novel Strategies for Immuno-Oncology Breakthroughs With Cell Therapy","volume":"9","author":"Liu","year":"2021","journal-title":"Biomark Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-016-0367-1","article-title":"T-Cell Receptor-Engineered T Cells for Cancer Treatment: Current Status and Future Directions","volume":"9","author":"Ping","year":"2018","journal-title":"Protein Cell"},{"key":"B115","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41421-018-0066-6","article-title":"A Novel Antibody-TCR (AbTCR) Platform Combines Fab-Based Antigen Recognition With Gamma\/Delta-TCR Signaling to Facilitate T-Cell Cytotoxicity With Low Cytokine Release","volume":"4","author":"Xu","year":"2018","journal-title":"Cell Discov"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2005.08.005","article-title":"BAFF-R, the Major B Cell-Activating Factor Receptor, is Expressed on Most Mature B Cells and B-Cell Lymphoproliferative Disorders","volume":"36","author":"Rodig","year":"2005","journal-title":"Hum Pathol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T Cells Targeting BAFF-R can Overcome CD19 Antigen Loss in B Cell Malignancies","author":"Qin","year":"2019","journal-title":"Sci Transl Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01477-x","article-title":"CD19\/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia","volume":"36","author":"Wang","year":"2022","journal-title":"Leukemia"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01159-5","article-title":"Modulating the Tumor-Associated Macrophage Landscape","volume":"23","author":"Boissonnas","year":"2022","journal-title":"Nat Immunol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000518664","article-title":"Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy","volume":"8","author":"Tian","year":"2022","journal-title":"Kidney Dis (Basel)"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \"Don't Eat Me\" Signal of CD47-Sirp\u03b1 in Hematological Malignancies, an in-Depth Review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2018.10.021","article-title":"Expression and Significance of CD47, PD1 and PDL1 in T-Cell Acute Lymphoblastic Lymphoma\/Leukemia","volume":"215","author":"Yang","year":"2019","journal-title":"Pathol Res Pract"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2238","article-title":"Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia","volume":"71","author":"Chao","year":"2011","journal-title":"Cancer Res"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-1700","article-title":"TTI-621 (Sirp\u03b1fc): A CD47-Blocking Innate Immune Checkpoint Inhibitor With Broad Antitumor Activity and Minimal Erythrocyte Binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3892\/or.17.5.1189","article-title":"Antitumor Activity of a Monoclonal Antibody Against CD47 in Xenograft Models of Human Leukemia","volume":"17","author":"Uno","year":"2007","journal-title":"Oncol Rep"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-19-1079","article-title":"Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody With Novel Anticancer Properties and Negligible Red Blood Cell Binding","volume":"19","author":"Puro","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000413","article-title":"The Fully Human Anti-CD47 Antibody SRF231 Exerts Dual-Mechanism Antitumor Activity via Engagement of the Activating Receptor CD32a","volume":"8","author":"Peluso","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-020-0571-2","article-title":"Preclinical Development of a Novel CD47 Nanobody With Less Toxicity and Enhanced Anti-Cancer Therapeutic Potential","volume":"18","author":"Ma","year":"2020","journal-title":"J Nanobiotechnol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"E10578","DOI":"10.1073\/pnas.1710877114","article-title":"Anti-Sirp\u03b1 Antibody Immunotherapy Enhances Neutrophil and Macrophage Antitumor Activity","volume":"114","author":"Ring","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B130","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13045-021-01163-6","article-title":"Sirp\u03b1-\u03b1cd123 Fusion Antibodies Targeting CD123 in Conjunction With CD47 Blockade Enhance the Clearance of AML-Initiating Cells","volume":"14","author":"Tahk","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0356-z","article-title":"Glutaminyl Cyclase is an Enzymatic Modifier of the CD47- Sirp\u03b1 Axis and a Target for Cancer Immunotherapy","volume":"25","author":"Logtenberg","year":"2019","journal-title":"Nat Med"},{"key":"B132","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","article-title":"Targeting CD47 for Cancer Immunotherapy","volume":"14","author":"Jiang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03010-6","article-title":"Modulation of CD47-Sirp\u03b1 Innate Immune Checkpoint Axis With Fc-Function Detuned Anti-CD47 Therapeutic Antibody","volume":"71","author":"Narla","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00432-021-03815-z","article-title":"Progress of CD47 Immune Checkpoint Blockade Agents in Anticancer Therapy: A Hematotoxic Perspective","volume":"148","author":"Chen","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-3706","article-title":"Phase I Study of the CD47 Blocker TTI-621 in Patients With Relapsed or Refractory Hematologic Malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate Lymphoid Cells: 10 Years on","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural Killer Cells: Development, Maturation, and Clinical Utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright Natural Killer (NK) Cells: An Important NK Cell Subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1159\/000365632","article-title":"Human Natural Killer Cells: Origin, Receptors, Function, and Clinical Applications","volume":"164","author":"Moretta","year":"2014","journal-title":"Int Arch Allergy Immunol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0061-z","article-title":"Natural Killer Cells and Other Innate Lymphoid Cells in Cancer","volume":"18","author":"Chiossone","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/nri2073","article-title":"Prospects for the Use of NK Cells in Immunotherapy of Human Cancer","volume":"7","author":"Ljunggren","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101702","article-title":"NK Cell-Based Immunotherapy for Hematological Malignancies","volume":"8","author":"Sivori","year":"2019","journal-title":"J Clin Med"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/3596983","article-title":"NK Cells as Possible Prognostic Factor in Childhood Acute Lymphoblastic Leukemia","volume":"2019","author":"Mizia-Malarz","year":"2019","journal-title":"Dis Markers"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-0479","article-title":"NK Cell Genotype and Phenotype at Diagnosis of Acute Lymphoblastic Leukemia Correlate With Postinduction Residual Disease","volume":"20","author":"Sullivan","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B146","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/2326-6066.CIR-21-0843","article-title":"Exploiting Natural Killer Cell Engagers to Control Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"10","author":"Colomar-Carando","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B147","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/bs.apcsb.2022.02.001","article-title":"Natural Killer Cell-Based Strategies for Immunotherapy of Cancer","volume":"129","author":"Van\u011bk","year":"2022","journal-title":"Adv Protein Chem Struct Biol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-022-00364-6","article-title":"CAR-NK Cells for Cancer Immunotherapy: From Bench to Bedside","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark Res"},{"key":"B149","doi-asserted-by":"publisher","first-page":"18729","DOI":"10.1038\/s41598-019-55239-y","article-title":"Adult Peripheral Blood and Umbilical Cord Blood NK Cells are Good Sources for Effective CAR Therapy Against CD19 Positive Leukemic Cells","volume":"9","author":"Herrera","year":"2019","journal-title":"Sci Rep"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03123","article-title":"High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia","volume":"10","author":"M\u00fcller","year":"2020","journal-title":"Front Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as Regulators of Tumour Immunity and Immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12580","article-title":"Macrophages: Sentinels and Regulators of the Immune System","volume":"18","author":"Franken","year":"2016","journal-title":"Cell Microbiol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1869389","article-title":"Advances in Identification and Selection of Personalized Neoantigen\/T-Cell Pairs for Autologous Adoptive T Cell Therapies","volume":"10","author":"Kast","year":"2021","journal-title":"Oncoimmunology"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690565","article-title":"Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges","volume":"12","author":"Lu","year":"2021","journal-title":"Front Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164245","article-title":"Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy","volume":"13","author":"Verdon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836821","article-title":"Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation","volume":"12","author":"Borden","year":"2022","journal-title":"Front Oncol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat8549","article-title":"Pediatric Patients With Acute Lymphoblastic Leukemia Generate Abundant and Functional Neoantigen-Specific CD8(+) T Cell Responses","volume":"11","author":"Zamora","year":"2019","journal-title":"Sci Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.921894\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T04:25:25Z","timestamp":1655094325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.921894\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":158,"alternative-id":["10.3389\/fimmu.2022.921894"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.921894","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"article-number":"921894"}}